A
Angela Grech
Researcher at Cardiff University
Publications - 7
Citations - 1099
Angela Grech is an academic researcher from Cardiff University. The author has contributed to research in topics: Induction chemotherapy & Myeloid leukemia. The author has an hindex of 5, co-authored 7 publications receiving 867 citations.
Papers
More filters
Journal ArticleDOI
Assessment of Minimal Residual Disease in Standard-Risk AML.
Adam Ivey,Robert Kerrin Hills,Michael A. Simpson,Jelena V. Jovanovic,Amanda F. Gilkes,Angela Grech,Yashma Patel,Neesa Bhudia,Hassan Farah,Joanne Mason,Kerry Wall,Susanna Akiki,Mike Griffiths,Ellen Solomon,Frank McCaughan,David C. Linch,Rosemary E. Gale,Paresh Vyas,Sylvie D. Freeman,Nigel H. Russell,Alan Kenneth Burnett,David Grimwade +21 more
TL;DR: Although mutations associated with preleukemic clones remained detectable during ongoing remission after chemotherapy, NPM1 mutations were detected in 69 of 70 patients at the time of relapse and provided a better marker of disease status.
Journal ArticleDOI
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Alan Kenneth Burnett,Nigel H. Russell,Robert Kerrin Hills,David T. Bowen,Jonathan Kell,Steven Knapper,Yvonne G Morgan,Jennie Lok,Angela Grech,Gail Jones,Asim Khwaja,Lone Smidstrup Friis,Mary Frances McMullin,Ann Hunter,Richard E. Clark,David Grimwade +15 more
TL;DR: A chemotherapy-free ATRA and arsenic trioxide treatment regimen with the standard chemotherapy-based regimen (ATRA and idarubicin) in both high-risk and low-risk patients with acute promyelocytic leukaemia is compared.
Journal ArticleDOI
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.
Paul Ferguson,Robert Kerrin Hills,Angela Grech,Sophie Betteridge,Lars Kjeldsen,Michael Dennis,Paresh Vyas,Anthony H. Goldstone,Donald Milligan,Richard E. Clark,Nigel H. Russell,Charles Craddock +11 more
TL;DR: Data demonstrate that allogeneic stem cell transplantation represents an effective therapeutic modality in selected patients with primary refractory acute myeloid leukemia and utilization of REF1 criteria permits the early identification of patients whose outcome after one course of induction chemotherapy is very poor.
Journal ArticleDOI
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia
Paul Milne,Charlotte Wilhelm-Benartzi,Michael R. Grunwald,Venetia Bigley,Richard Dillon,Sylvie D. Freeman,Kathleen Gallagher,Amy Publicover,Sarah Pagan,Helen Marr,Gail Jones,Anne M. Dickinson,Angela Grech,Alan Kenneth Burnett,Nigel H. Russell,Mark Levis,Steven Knapper,Matthew Collin +17 more
TL;DR: Serial measurement of Flt3L in patients who had received a hematopoietic stem cell transplant for AML illustrates the potential value of monitoring Flt2L to identify relapse and retains a near-significant association with survival after adjusting for MRD in a proportional hazards model.
Journal ArticleDOI
An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts.
Naeem Khan,Sylvie D. Freeman,Paul Virgo,Steve Couzens,Peter Richardson,Ian Thomas,Angela Grech,Paresh Vyas,David Grimwade,Nigel H. Russell,Alan Kenneth Burnett,Robert Kerrin Hills +11 more
TL;DR: A flow cytometric assay measuring pre‐treatment CD34+ CD38low blast frequency could predict therapeutic‐resistance in 736 AML patients entered into the UK National Cancer Research Institute AML16 trial and was independently prognostic for all endpoints of treatment resistance by multivariate analysis.